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Abstract 
Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is 
chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used 
in the treatment of depression and bipolar disorder. But it is a bitter drug and 
slightly soluble in water. Thus, in the work under taken, an attempt was made 
to mask the taste and to formulate into a chewable dispersible tablet by 
complexation with Precirol ATO-05, which also acts as taste masking agent. 
Since, these tablets can be swallowed in the form of dispersion; it is suitable 
dosage form for paediatric and geriatric patients. Drug-Precirol ATO-05 was 
prepared in drug to Precirol ATO-05 ratio of 1:2, 1:1.5, 1:1, 1:0.5. The 
prepared tablets were evaluated for general appearance, content uniformity, 
hardness, friability, taste evaluation, mouth feel, in vitro disintegration time, 
and in vitro dissolution studies. Tablets with Precirol ATO-05 have shown 
good disintegrating features, also, the dispersion not showing any bitter taste, 
indicate the capability of Precirol ATO-05 used, both as taste masking agents. 
Almost more than 90 percent of drug was released from the formulation 
within 1 h. Further formulations were subjected to stability testing for 3 
months at temperatures 25±5ºC/60±5%RH; 30±5ºC/65±5%RH and 
40±5ºC/75±5%RH. Tablets have shown no appreciable changes with respect 
to taste, disintegration, and dissolution profiles. 
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Introduction  
The bitter taste of the drugs which are orally 
administered often contributes to patient non-
compliance in taking medicines, especially for 
children and elderly [1]. Unfortunately, majority of 
the drugs have a natural bitter taste that can create a 
burning feeling in the throat or in the mouth. In 
particular, a bitter taste can decrease the patient 
compliance and thus reducing an effective 
pharmacotherapy. In order to achieve an acceptable 
palatability, the  addition  of  flavors  or sweeteners is  
 
limited and may not be efficient enough to mask the 
taste buds of drugs and requires the use of 
technological processes [2]. A number of taste 
masking approaches like the use of ion exchange 
resins [3], the use of inclusion complexes with 
cyclodextrins [4], viscosity modifications [5] and melt 
granulation [6] have been described. More than 50 
percent of pharmaceutical products are orally 
administered for several reasons and undesirable taste 
is one of the important formulation problem 
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encountered with such oral products [7]. The taste of 
a pharmaceutical product is an important parameter 
for governing compliance. Thus, taste masking of oral 
pharmaceuticals has become an important tool to 
improve patient compliance and the quality of 
treatment especially in pediatrics. Therefore, 
formulation of taste masked products is a challenge to 
the pharmacists [8, 9]. 
In recent decades, a variety of research has been 
conducted to develop new dosage forms. Considering 
quality of life, most of these efforts have been 
focused on ease of medication [10]. Among the 
dosage forms developed to facilitate ease of 
medication, the chewable dispersible tablet (CDT) is 
one of the most widely employed commercial 
products. The CDT has remarkable disintegration 
properties; it can disintegrate without water in the 
mouth. CDTs are useful in patients such as pediatric, 
geriatric, bedridden, or developmentally disabled who 
may face difficulty in swallowing conventional 
tablets or capsules leading to ineffective therapy, 
persistent nausea, sudden episodes of allergic attacks, 
or coughing. CDTs are also applicable when local 
action in the mouth is desirable such as local 
anesthetic for toothaches, oral ulcers, cold sores, or 
teething and to deliver sustained release 
multiparticulate system to those who cannot swallow 
intact sustained action tablets/capsules. Chewable 
tablets are formulated and manufactured so that they 
may be chewed, producing a pleasant tasting residue 
in the oral cavity that is easily swallowed and does 
not leave a bitter or unpleasant aftertaste. Chewable 
tablets are prepared by compression, usually   
utilizing, sorbitol, or sucrose as binders and fillers, 
and containing colors and flavors to enhance their 
appearance and taste. Chewable dispersible tablets 
have the advantages like better bioavailability through 
bypassing disintegration (and perhaps enhancing 
dissolution), patient convenience through the 
elimination of the need for water for swallowing, 
possible use as a substitute for liquid dosage forms 
where rapid onset of action is needed, improved 
patient acceptance through pleasant taste, and product 
distinctiveness from marketing perspective. Chewable 
dispersible tablets represent the largest market 
segment of chewable dosage forms.  
Melt granulation is a process by which 
pharmaceutical powders are efficiently agglomerated 
by the use of a binder which can be a molten liquid or 
a solid that melts during the process. [11]. Melt 
granulation has been successfully applied to develop 
sustained release formulations, taste masked 
formulations with lipophillic melting binders, such as 
glycerol monostearate, a combination of a 
hydrophobic materials, a starch derivative  and 
Stearic acid among others [12-15]. 
Lamotrigine, an antiepileptic drug (AED) of the 
phenyltriazine class, is chemically unrelated to 
existing antiepileptic drugs. Lamotrigine is also used 
in the treatment of depression and bipolar disorder. 
Lamotrigine is thought to exert its anticonvulsant 
effect by stabilizing presynaptic neuronal membranes. 
Lamotrigine inhibits sodium currents by selectively 
binding to the inactivated state of the sodium channel 
and subsequently suppresses the release of the 
excilatory amino acid, glutamate. 
 Lamotrigine is very slightly soluble in water (0.17 
mg/mL at 25°C) and slightly soluble in 0.1 M HCl 
(4.1 mg/mL at 25°C),having plasma half life of 24 to 
35 hours [16]. In the present study it was proposed to 
formulate an oral delivery device in the form of 
chewable dispersible tablets of Lamotrigine using 
melt granulation technology using disintegrant 
Crosspovidone and taste masking agent Precirol 
ATO-05 with the aim of high drug serum 
concentration in a short period of time. The effect of 
different concentrations of disintegrant on 
disintegration time and effect of Precirol ATO-05 on 
taste masking and drug release was studied. 
 
Materials and methods 
Materials  
Lamotrigine was obtained from Watson Pharma Pvt. 
Ltd. Ambernath, Thane. Crosspovidone and sodium 
starch glycol ate was kindly donated by Cromovideo, 
Italy and Scientific and Surgical Corporation, 
Mumbai respectively.  Precirol ATO-05, Pearlitol SD 
200, aspartame, sodium chloride, mint flavour, 
peppermint flavour were kindly donated by Watson 
Pharma Pvt. Ltd. Ambernath, Thane. Stearic acid, 
Tween 80, magnesium stearate, talc and colloidal 
silicone dioxide were obtained from Beijing Jingqiu 
Chemical Industry Co. Ltd. Beijing, China.   
     
Compatibility study  
Amrutkar et al. International Journal of Drug Delivery 2 (2010) 183-191 
 185
The compatibility study was carried out to study the 
interaction between the drug Lamotrigine and 
excipients. Lamotrigine was mixed separately with 
the excipients at an appropriate ratio. Each mixture 
was  stored  in  an  open   glass   bottle  at   40°C/75%  
relative humidity (RH) for 1 week. Lamotrigine was 
also stored alone as a reference. The interaction 
between the drug and excipients was then assayed 
using FT-IR.  
 
 
Table 1. Formulation design of Lamotrigine chewable dispersible tablet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of chewable dispersible tablets 
The formulation design for different batches of 
chewable dispersible tablets of Lamotrigine is given 
in Table 1. The required quantity of Precirol ATO-05 
was weighed. It was melted in porcelain dish at 75 0C 
- 80 0C for 5 min and Tween 80 was added in it.  The 
molten mixture was added to a mixture of 
Lamotrigine (25mg) and Crosspovidone. The molten 
mixture was allowed to cool and solidify at room 
temperature. The solidified mass was crushed in 
mortar and passed through a 16 mesh sieve and thus 
granules were prepared. 
The granules, Pearlitol SD200, aspartame, 
Crosspovidone (superdisintegrant), colloidal silicon 
dioxide and mixed fruit flavors were admixed for 
about 15 min to make a uniform blend. Magnesium  
Stearate was passed through sieve 100 and mixed 
with the above blend for approximately 5-7 min.   
 
Characterization of powder blend of active 
pharmaceutical ingredient and excipients 
The powder blend of formulation as shown in Table 1 
was evaluated for following flow properties. 
Angle of repose  
Angle of repose was determined using funnel method 
[17]. The blend was poured through a funnel that can 
be raised vertically until a maximum cone height (h) 
was obtained. Radius of the heap (r) was measured 
and angle of repose (q) was calculated using the 
following formula:        
r
hq 1tan−=
 
Bulk density  
Ingredients (mg) F1 F2 F3 F4 F5 F6 
Hydrochlorothiazide 25 25 25 25 25 25 
Crosspovidone - - - - 10.5 125 
Precirol ATO-05 50 37.5 - - 50 50 
Tween-80 0.4 0.75 - - 1.25 1.50 
Pearlitol SD-200 96 65.25 142.5 102.5 49.2 47.8 
Cherry flavor 3 2.25 2.25 3 2.25 2.25 
Mint flavor 0.75 0.56 0.25 0.75 0.56 0.56 
Sodium chloride 0.75 0.56 - 0.75 0.56 0.56 
Aspartame 4 3 4 4 3 3 
Aerosil 5 3.75 5 5 3.75 3.75 
Magnesium stearate 5 3.75 5 5 3.75 3.75 
Sodium starch glycol ate 10 7.5 10 10 - - 
Eudragit EPO - - 1 2.5 - - 
Stearic acid - - 2 1.5 - - 
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Apparent bulk density ( ρ b) was determined by 
pouring the blend into a graduated cylinder. The bulk 
volume (Vb) and weight of the powder (M) was  
 
 
 
determined. The bulk density ( ρ b) was calculated 
using following formula [17], 
M
Vb
b =ρ
Table 2. Characterization of formulation blends of Lamotrigine and excipients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tapped density  
The measuring cylinder containing a known mass of 
blend (M) was tapped for a fixed time (100 tapping). 
The minimum volume (Vt) occupied in the cylinder 
and weight of the blend was measured. The tapped 
density ( ρ t) was calculated using following formula 
[17], 
M
Vt
t =ρ  
 
Compressibility index  
The simplest method of measurement of free flow of 
powder is compressibility. An indication of the ease 
with which material can be induced to flow is given 
by compressibility index (I) which is calculated as 
follows [17], 
100×−=
t
btI ρ
ρρ
 
 
 
Where ρ t indicates the tapped density; ρ b indicates 
the bulk density.  
 
Hausner’s ratio (H)  
This is an indirect index of ease of powder flow. It is 
calculated by the following formula [17], 
b
t
ρ
ρ=Η
 
Where ρ t indicates the tapped density; ρ b indicates 
the bulk density. 
 
Compression of powder blend  
The resulting powder blends were directly 
compressed using 8 mm, round flat faced tooling to 
make the tablets of said compression specifications; 
using 8 station RIMEK compression machine. The 
tablet press setting was kept constant for all batches 
of formulations. 
 
 
Parameter F1 F2     F3 F4 F5 F6 
Angle of 
Repose 
24.15±0.1 27.40±0.1 26.17±0.03 27.17±0.01 28.45±0.05 27.38 ±0.0 
Bulk 
Density(g/cm3) 
0.492±0.0 0.464±0.01 0.477 ±0.00 0.486±0.2 0.526±0.02 0.544±0.03 
Tapped 
Density(g/cm3) 
0.538±0.01 0.559±0.01 0.589±0.1 0.593±0.0 0.662±0.1 0.660±0.0 
Compressibilit
y Index (%) 
10.42±1.21 10.52±1.21 12.74±0.09 12.07±1.14 14.64±1.04 13.85±0.40 
Hausner’s 
Ratio 
1.12±0.014 1.12±0.015 1.148±0.01 1.137±0.01 1.181 ±0.01 1.158±0.00 
Flowability Excellent Excellent Excellent Excellent Excellent Excellent 
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Table 3. Evaluation of prepared Lamotrigine taste masked chewable dispersible tablets. 
 
Evaluation parameters F1 F2 F3 F4 F5 F6 
Average Weight (mg) 150 150 150 150 150 150 
Thickness (mm) 3.20-3.4 3.2-3.5 3.24-3.30 3.23-3.35 3.28-3.30 3.24-3.30 
Hardness (Kg/cm2) 3.2-3.3 3.2-3.8 3.3-3.7 3.2-3.7 3.2-3.30 5.3-5.6 
Friability (%) 0.512 0.528 0.312 0.298 0.265 0.219 
Disintegration time (sec) 540 458 203 130 152 148 
Drug Content (%) 102.36 100.23 98.45 98.43 99.69 99.24% 
Cumulative drug release (%) 73.26 82.02 47.34 62.19 83.20 99.15% 
 
 
Evaluation of chewable dispersible tablets  
The various standards or quality control tests carried 
out on compressed tablets as follows: 
General appearance, thickness and hardness test 
Five tablets from all batches were randomly selected  
and organoleptic properties such as color, odor and 
shape were evaluated. The thickness and diameter of 
five tablets was measured using Vernier caliper. 
Hardness of the tablets was tested by using Monsanto 
hardness tester [18]. 
 
 
Table 4. Comparative dissolution profile of chewable dispersible tablets in 0.1N HCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug content uniformity 
Twenty tablets were weighed and powdered. The 
blend equivalent to 25 mg was weighed and dissolved 
in sufficient quantity of 0.1M HCl. The solution was 
filtered through Whatmann filter paper (no.41), 
suitably   diluted   with   0.1M   HCl   and  assayed  at 
267.0nm using a UV-Visible double beam 
spectrophotometer [19].  
Weight variation and friability test  
Weight variation test was performed by weighing 20  
tablets individually; calculating the average weight 
and comparing the individual tablet weight to the 
average. Friability test is performed to assess the 
effect of friction and shocks, which may often cause 
tablet to chip, cap or break. Roche Friabilator was 
used for this purpose. This device subjects a number 
of tablets to the combined effect of abrasion and 
shock by utilizing a plastic chamber that revolves at 
25 rpm dropping the tablets at a distance of 6 inches 
with each revolution. Preweighed sample of tablets 
Cumulative % Drug Release Time 
(min) F1 F2 F3 F4 F5 F6 
5 16.646 46.18 7.54 22..63 29.29 40.64 
10 39.189 54.36 10.43 29.02 40.315 59.55 
20 58.58 62.30 24.22 38.28 51.63 74.06 
30 64.27 64.87 37.24 50.98 61.32 80.72 
40 64.75 70.34 40.42 53.995 68.65 83.55 
50 69.17 75.31 46.65 56.15 76.58 87.07 
60 73.26 82.02 47.34 62.19 83.20 99.15 
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was placed in the Friabilator, which was then 
operated for 100 revolutions. Tablets were dusted and 
reweighed. Compressed tablets should not loose more 
than 1% of their weigh [20]. 
 
 
Table 5. Result of taste experiments. 
Score of taste test 
F1 F2 F3 F4 F5 F6  
No. of 
peoples score 
No. of 
peoples score 
No. of 
peoples score 
No. of 
peoples score 
No. of 
peoples score 
No. of 
peoples score 
No bitter 
taste 0 0 0 0 0 0 0 0 1 0 6 0 
Slight 
bitter taste 0 0 4 0 0 0 4 4 0 0 1 5 
Strong 
bitter taste 6 18 5 15 6 18 2 6 5 15 0 0 
Mean score 
overall 
evaluation 
- 03 - 1..66 - 03 - 1.66 - 03 - 0.71 
 
In vitro disintegration test  
For a drug to be absorbed from a solid dosage form 
after oral administration it must first be in solution 
and the first important step toward this condition is 
usually the break-up of the tablet, a process known as 
disintegration. The disintegration time of tablet was 
measured in water (370C) according to USP 
Disintegration test apparatus. Three trials for each 
batch were performed (20). 
 
 In Vitro dispersion test  
 In vitro dispersion time was measured by dropping a 
tablet in a measuring cylinder containing 6 ml of 
simulated salivary fluid of pH 6.8. Five tablets from 
each formulation were randomly selected and in vitro 
dispersion time was determined [20].   
 
In vitro dissolution studies 
The release rate of HCT from chewable dispersible 
tablet was determined using USP dissolution testing 
apparatus II (paddle type). The dissolution test was 
performed using 900 ml of 0.1 N HCL, at 37±0.5 0C 
and at 50rpm sample (5 mL) was withdrawn from the  
 
dissolution apparatus every 2 min. for 30 min, and it 
was replaced with fresh dissolution medium. The 
samples were filtered through Whatman filter paper 
no. 41. Absorbance of these solutions was measured 
at 267nm UV spectrophotometer Shimadzu 1700. 
 
Taste evaluation 
Single blind study was designed for the taste masking 
test and disintegration time in the buccal cavity. Six 
volunteers participated in the test. They were asked to 
rate the bitter taste of the three formulations 
(formulation 1–3) using a scale of 0–3. When the 
score was 1 or less, the taste was considered as 
acceptable. If the score was higher than 1, the 
bitterness of the formulation was not acceptable [21].  
 
Mouth feel 
The same human volunteers who participated in taste 
evaluation test were asked to give their opinion about 
the feeling of smoothness or grittiness of the 
dispersion soon after the tablet got disintegrated [22]. 
 
Wetting time  
The wetting time of tablets was measured using a 
simple procedure [23]. A piece of tissue paper folded 
twice was placed in a small Petri dish containing 10 
ml of distilled water. A tablet having amaranth 
powder on the upper surface was placed on the filter 
paper. Time required to develop red color on the 
upper surface of tablet was recorded as wetting time. 
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Stability studies 
Stability studies were carried out at 
25±5°C/60±5%RH; 30±5°C/65±5%RH and 
40±5°C/75±5%RH for a period of 1, 2 and 3 months 
for the formulations as per ICH guidelines. 
 
Result and discussion 
IR spectroscopy was used as means of studying drug-
excipients compatibility which indicates no drug-
excipients interaction. 
The value of compressibility index below 15% 
indicates a powder which usually gives rise to 
excellent flow characteristics, whereas above 25% 
indicate poor flowability. Lower Hausner’s ratio 
(<1.25) indicates better flow properties than higher 
ones (>1.25). The following table shows the 
characterization of each formulation. 
The size and shape of the tablet can also affect the 
disintegration time and subsequent dissolution profile. 
The size of the tablet was 8 mm and shape of tablet 
was flat round oval.  The color of the tablet was white 
and the flavor is which on the basis of flavor added 
which is patient compliant. Tablet crushing strength, 
the critical parameter was controlled as the resistance 
of tablets to capping, abrasion or breakage under 
conditions of storage, transportation and handling 
before usage depends on its hardness. The hardness 
for all formulation batches i.e. F1 to F6 was found to 
be between 3.2-5.6 Kg/cm2. Thickness for all 
formulation batches i.e. F1 to F6 was found to be 
between 3.21 to 3.46 mm.  
Drug content for all formulation batches i.e. F1 to F6 
was found to be in the range of 98.43and 103.36%.  
Uniformity of content for all formulation batches i.e. 
F1 to F6 was found to be in the range of 98.00 to 
101.99%. Uniform weight due to uniform die fill with 
acceptable variation as per standards was obtained 
since blend of material was free-flowing. The percent 
deviation in weight variation for all formulation 
batches i.e. F1 to F6 was found to be 150mg ± 1.0%. 
Hence, weight variation test for all batches of tablets 
comply specifications. The % friability values for all 
formulation batches i.e. F1 to F6 were found to be 
between 0.200 to 0.500%.  
Disintegration time is an important criterion for 
selecting an optimum CDT formulation. Several 
methods have been described for evaluating in vitro 
disintegration time of CDT formulations. It was 
observed that decreasing the concentration of 
Precirol-ATO resulted in a decrease in disintegration 
time. The in-vitro disintegration of CDTs shows 
disintegration time from 540-148 seconds. From this 
result it was concluded that the disintegration time of 
the formulated batches is in the range. 
This test is performed to ensure disintegration of 
tablets in the salivary fluid, if it is to be used as a 
chewable-dispersible tablet, mouth dissolving, oro-
dispersible tablets. The in-vitro dispersion time shows 
better chewable and dispersion of tablet in the 
salivary fluid pH 6.8. 
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Figure 1. Comparative dissolution profile of HCTz 
formulations. 
 
The mean score less than 1 for the formulation 6 
indicated that the formulation containing Precirol 
ATO-05 sufficiently alleviate the bitterness of CDT 
tablets. F6 formulation did not show any bitter taste 
when tablets are held in the mouth by using time 
intensity method, which shows excellent taste 
masking effect of the Precirol ATO-05. The Precirol 
in 1:2 proportions with drug gives better taste 
masking, which did not show any result on drug 
release. 
All formulations show smooth and pleasant mouth 
feeling, but formulation F6 shows better mouth feel as 
compare to other formulations thus fulfill the 
requirements of chewable-dispersible tablets. As 
increase the concentration of the Precirol there is 
bitterness of the formulation as reduces the 
concentration better mouth feeling effect. The wetting 
time was rapid in Crosspovidone followed by Sodium 
starch glycol ate. Here also it was observed that as the 
concentration of disintegrant increased the time taken 
for wetting was reduced. As the concentration of 
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Crosspovidone was increased from formulation F4 to 
F6 the wetting time was reduced. 
There was no color, and odor change at any 
temperature. There is no change in the in vitro 
dispersion time, in vitro disintegration time, and in 
vitro dissolution profiles after three months of 
stability studies for F6 formulation at different 
temperatures. 
Precirol ATO-05 could not retard the release in 
optimized formulation but it acts as taste masking 
agent. The amount of Precirol ATO-05 used affects 
the taste masking and drug release profile. So the 
optimized formulation is suitable for geriatric patients 
in treatment of epilepsy and for bipolar diseases in 
patients older than 2 yrs of an age.  which gives better 
taste masking and fast onset of action as compared to 
conventional tablet.  
 
Conclusion 
In conclusion, we achieved our objective of preparing 
chewable dispersible tablets of Lamotrigine by melt 
granulation. Also a prerequisite, taste masking of 
Lamotrigine by preparing a taste masked granules of 
Lamotrigine with Precirol ATO-05. These patient 
compliant tablets that had a good taste and are useful 
for pediatric and geriatric populations and can be 
commercialized 
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